Segment Information (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Information

The following tables set forth our segment information for the three months ended March 31, 2024 and 2023 (in thousands):

	Three Months Ended March 31, 2024
	MRD			Immune Medicine			Unallocated Corporate			Total
Revenue	$	32,626		$	9,247		$	—		$	41,873
Operating expenses		59,886			23,841			6,908			90,635
Adjusted EBITDA(1)		(17,259	)		(6,927	)		(3,994	)		(28,180	)
Reconciliation of Net Loss to Adjusted EBITDA:
Net loss	$	(27,260	)	$	(14,593	)	$	(5,680	)	$	(47,533	)
Net loss attributable to noncontrolling interest		—			—			26			26
Net loss attributable to Adaptive Biotechnologies Corporation		(27,260	)		(14,593	)		(5,654	)		(47,507	)
Interest and other income, net		—			—			(4,222	)		(4,222	)
Interest expense(2)		—			—			2,993			2,993
Depreciation and amortization expense		2,701			2,082			431			5,214
Restructuring expense(3)		467			577			—			1,044
Share-based compensation expense(4)		6,833			5,007			2,458			14,298
Adjusted EBITDA(1)	$	(17,259	)	$	(6,927	)	$	(3,994	)	$	(28,180	)

	Three Months Ended March 31, 2023
	MRD			Immune Medicine			Unallocated Corporate			Total
Revenue	$	21,427		$	16,220		$	—		$	37,647
Operating expenses		56,025			31,672			7,143			94,840
Adjusted EBITDA(1)		(26,386	)		(7,427	)		(3,285	)		(37,098	)
Reconciliation of Net Loss to Adjusted EBITDA:
Net loss	$	(34,597	)	$	(15,452	)	$	(7,651	)	$	(57,700	)
Net loss attributable to noncontrolling interest		—			—			1			1
Net loss attributable to Adaptive Biotechnologies Corporation		(34,597	)		(15,452	)		(7,650	)		(57,699	)
Interest and other income, net		—			—			(3,024	)		(3,024	)
Interest expense(2)		—			—			3,531			3,531
Depreciation and amortization expense		2,056			2,753			614			5,423
Share-based compensation expense(4)		6,155			5,272			3,244			14,671
Adjusted EBITDA(1)	$	(26,386	)	$	(7,427	)	$	(3,285	)	$	(37,098	)

(1) Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation for how it is calculated and used by management.

(2) Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement.

(3) Represents costs associated with our organizational realignment to our two segments initiated in the three months ended March 31, 2024. These costs primarily related to one-time termination benefits and ongoing benefit arrangements.

(4) Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense.